Full Press Release Details
Ultragenyx Announces U.S. Commercial Launch of Dojolvi (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders.
RARE
Ultragenyx Announces U.S. Commercial Launch of Dojolvi (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders
Key Takeaway: Ultragenyx Announces U.S. Commercial Launch of Dojolvi (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders